NeoPharm, Inc. (NASDAQ: NEOL) has enrolled its first patients in its multi-center open-label, Phase II clinical trial of Liposomal Paclitaxel ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE